Halozyme Therapeutics (NASDAQ:HALO) Earns “Buy” Rating from HC Wainwright

Halozyme Therapeutics (NASDAQ:HALO)‘s stock had its “buy” rating reiterated by equities researchers at HC Wainwright in a research report issued on Friday,Benzinga reports. They currently have a $90.00 target price on the biopharmaceutical company’s stock. HC Wainwright’s price target points to a potential upside of 38.23% from the stock’s current price.

Several other equities analysts have also weighed in on HALO. Leerink Partnrs raised shares of Halozyme Therapeutics from a “strong sell” rating to a “hold” rating in a report on Tuesday, October 14th. Wall Street Zen lowered shares of Halozyme Therapeutics from a “strong-buy” rating to a “buy” rating in a research report on Saturday, December 6th. Zacks Research downgraded shares of Halozyme Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Monday, October 6th. Citigroup reissued a “market outperform” rating on shares of Halozyme Therapeutics in a research note on Tuesday, November 4th. Finally, Citizens Jmp lifted their price target on Halozyme Therapeutics from $91.00 to $92.00 and gave the company a “market outperform” rating in a research note on Tuesday, November 4th. Six equities research analysts have rated the stock with a Buy rating, seven have assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, Halozyme Therapeutics presently has a consensus rating of “Hold” and a consensus target price of $75.10.

Halozyme Therapeutics Stock Performance

Shares of HALO stock opened at $65.11 on Friday. Halozyme Therapeutics has a 52-week low of $46.26 and a 52-week high of $79.50. The company has a quick ratio of 1.37, a current ratio of 1.59 and a debt-to-equity ratio of 1.59. The stock has a market cap of $7.66 billion, a PE ratio of 13.71, a price-to-earnings-growth ratio of 0.36 and a beta of 0.95. The business has a 50-day simple moving average of $67.07 and a 200-day simple moving average of $64.82.

Halozyme Therapeutics (NASDAQ:HALO) last posted its earnings results on Monday, November 3rd. The biopharmaceutical company reported $1.72 EPS for the quarter, topping the consensus estimate of $1.63 by $0.09. The firm had revenue of $354.26 million for the quarter, compared to analyst estimates of $339.18 million. Halozyme Therapeutics had a return on equity of 156.95% and a net margin of 47.91%.Halozyme Therapeutics’s revenue for the quarter was up 22.1% compared to the same quarter last year. During the same period last year, the company earned $1.27 earnings per share. On average, equities analysts expect that Halozyme Therapeutics will post 4.73 EPS for the current year.

Insider Transactions at Halozyme Therapeutics

In other Halozyme Therapeutics news, CEO Helen Torley sold 16,569 shares of the business’s stock in a transaction that occurred on Monday, December 1st. The stock was sold at an average price of $68.92, for a total transaction of $1,141,935.48. Following the completion of the sale, the chief executive officer directly owned 708,719 shares in the company, valued at approximately $48,844,913.48. The trade was a 2.28% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CFO Nicole Labrosse sold 2,227 shares of the stock in a transaction that occurred on Monday, September 22nd. The shares were sold at an average price of $77.95, for a total value of $173,594.65. Following the transaction, the chief financial officer directly owned 22,079 shares of the company’s stock, valued at $1,721,058.05. The trade was a 9.16% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold 83,625 shares of company stock valued at $5,932,527 over the last 90 days. Corporate insiders own 2.40% of the company’s stock.

Institutional Trading of Halozyme Therapeutics

Several large investors have recently made changes to their positions in HALO. Lindenwold Advisors INC raised its stake in Halozyme Therapeutics by 2.5% in the 3rd quarter. Lindenwold Advisors INC now owns 8,221 shares of the biopharmaceutical company’s stock valued at $603,000 after purchasing an additional 201 shares during the last quarter. Allworth Financial LP lifted its stake in shares of Halozyme Therapeutics by 322.5% in the third quarter. Allworth Financial LP now owns 39,736 shares of the biopharmaceutical company’s stock worth $2,914,000 after buying an additional 30,331 shares in the last quarter. IFP Advisors Inc boosted its position in Halozyme Therapeutics by 17.8% during the third quarter. IFP Advisors Inc now owns 5,206 shares of the biopharmaceutical company’s stock worth $382,000 after acquiring an additional 785 shares during the last quarter. Swiss Life Asset Management Ltd purchased a new stake in Halozyme Therapeutics during the 3rd quarter valued at about $426,000. Finally, CIBC Private Wealth Group LLC grew its stake in Halozyme Therapeutics by 12.8% during the 3rd quarter. CIBC Private Wealth Group LLC now owns 2,891 shares of the biopharmaceutical company’s stock valued at $212,000 after acquiring an additional 329 shares in the last quarter. 97.79% of the stock is currently owned by hedge funds and other institutional investors.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.